# Development and Validation of a Prognostic Model to Predict Mortality in Patients With Heart Failure With Mildly Reduced Ejection Fraction After Acute Myocardial Infarction

## TL;DR

This study created a model to predict mortality risk in heart failure patients after heart attacks, using factors like age and kidney function.

## Contribution

A novel prognostic model was developed and validated for mortality prediction in HFmrEF patients following AMI.

## Key findings

- Six predictors (age, stroke history, NYHA classification, hemoglobin, eGFR, PPCI) were identified for mortality risk.
- The model showed good predictive performance with C-indexes of 0.795 in training and 0.741 in validation cohorts.
- AUC metrics indicated strong survival prediction across multiple time points in the training cohort.

## Abstract

Accurately assessing mortality risk in patients with heart failure with mildly reduced ejection fraction (HFmrEF) after acute myocardial infarction (AMI) remains challenging. This study developed and validated a mortality risk predictive model for such patients.

In this single-center retrospective study of 873 hospitalized patients with HFmrEF after AMI, 611 patients were included in the training cohort and 262 in the validation cohort. The primary outcome was all-cause mortality over an average 33-month follow-up. Least absolute shrinkage and selection operator (LASSO) regression identified predictive variables for post-discharge mortality, with model performance assessed via receiver operating characteristic (ROC) analysis and decision curve analysis (DCA).

Six mortality risk predictors were identified: age, stroke history, New York Heart Association (NYHA) classification, hemoglobin (Hb) levels, estimated glomerular filtration rate (eGFR), and primary percutaneous coronary intervention (PPCI) implementation. The C-index for training and validation cohorts was 0.795 (95% confidence interval (CI), 0.758–0.832) and 0.741 (95% CI, 0.672–0.81), respectively. Training cohort area under the curve (AUC) metrics for 6-month, 2-year, and 3-year survival were 0.861, 0.805, and 0.815; for the validation cohort, they were 0.722, 0.742, and 0.736.

A validated predictive model assessing mortality risk in HFmrEF patients post-AMI was established. External validation in future studies is recommended.